Physician profile
Hannah Nealey
NPI 1649793167
$75,286.58
in general payments reported to CMS, 2019-2025
32 companies · $6,398 in 2025
The $6,398 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $21K · 2023: $31K · 2024: $4,609 · 2025: $6,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $6,969 · Travel and Lodging: $3,779 · Consulting Fee: $173 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,180.00 |
| Food and Beverage | $6,969.04 |
| Travel and Lodging | $3,778.98 |
| Consulting Fee | $172.50 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66,236.21 | 2021-2025 | |
| Corium, LLC | $1,589.33 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,053.95 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $622.81 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $560.72 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $541.84 | 2021-2024 | Spravato |
| Alkermes, INC. | $533.84 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $456.09 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $440.61 | 2021-2024 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $434.39 | 2021-2024 | Rexulti |
| Bausch Health US, LLC | $342.76 | 2021-2024 | Aplenzin |
| Axsome Therapeutics, INC. | $299.33 | 2023-2024 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $294.99 | 2021-2024 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $240.31 | 2021-2022 | |
| Neuronetics, INC. | $228.57 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $220.24 | 2022-2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $153.18 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $142.40 | 2023 | Jornay Pm |
| Tris Pharma INC | $128.41 | 2022-2024 | Dyanavel Xr |
| Validus Pharmaceuticals LLC | $116.91 | 2022-2024 | Equetro |
| Eisai INC. | $92.67 | 2021-2022 | |
| Adlon Therapeutics L.P. | $84.82 | 2021 | |
| Merck Sharp & Dohme LLC | $76.54 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $64.55 | 2025 | Cobenfy |
| Almatica Pharma LLC | $62.32 | 2022-2024 | Loreev Xr |
| Noven Therapeutics, LLC | $53.19 | 2023-2024 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $49.20 | 2021-2022 | |
| Indivior INC. | $47.34 | 2021-2022 | |
| Neos Therapeutics, LP | $46.55 | 2021-2024 | Adzenys Xr-Odt |
| Novo Nordisk INC | $29.86 | 2021-2022 | |
| Alfasigma USA, INC. | $23.82 | 2022 | |
| Uswm, LLC | $18.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Nealey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.